

## PACIFIC EDGE RETAIL OFFER CLOSING DATE REMINDER

Cancer diagnostics business, Pacific Edge Limited (NZX/ASX: PEB) would like to remind Eligible Shareholders<sup>1</sup> of the opportunity to subscribe for new ordinary shares (**Shares**) in Pacific Edge through the Retail Offer.

**The Retail Offer closes at 5.00pm NZDT on Wednesday 13 October 2021.**

The Offer is part of Pacific Edge's equity raising announced on 23 September 2021 which also included a successful NZ\$80 million (A\$77.5 million) upsized placement to institutional and other eligible investors (**Placement**). Pacific Edge is seeking to raise up to a further NZ\$20 million (A\$19.4 million) by way of the Offer to eligible New Zealand shareholders. However, Pacific Edge can accept oversubscriptions at its absolute discretion.

### Participating in the Offer

Eligible Shareholders can participate in the Offer online at <https://pacificedge.capitalraise.co.nz>. To complete an acceptance online Eligible Shareholders will need their Holder Number and the unique Entitlement Number stated below. Eligible Shareholders should complete their application allowing sufficient time for it to be received by **5.00pm NZDT on Wednesday 13 October 2021**.

**If you have completed your application recently, you do not have to take any further action.**

### About the Offer

The Offer will enable all eligible New Zealand shareholders of Pacific Edge Limited to participate in the equity raising and acquire new Shares, with a minimum application amount of NZ\$250.00 and a maximum application amount of NZ\$50,000.

The issue price per Share will be the lower of NZ\$1.35 (being the price paid by investors under the Placement) and the volume weighted average price of Shares over the 5-day trading period before the Closing Date of the Offer (being 13 October 2021, unless extended).

The proceeds of the equity raising will be used to accelerate growth into the company's key market, the United States (US), to further growth in Southeast Asia, to increase investment in research and development of PEL's current product range (Cxbladder), and also to potentially develop and grow new product opportunities by leveraging intellectual property across other cancers that can be detected in urine. The proceeds of the equity raising will also provide Pacific Edge with additional balance sheet flexibility. Further details about the proposed use of proceeds are set out in the Investor Presentation released by Pacific Edge on 23 September 2021 in connection with the equity raising.

Further details about the Retail Offer are included in the Offer Document which can be viewed online at <https://pacificedge.capitalraise.co.nz>

ENDS

**For more information contact:** David Darling, Chief Executive Officer, Pacific Edge Ltd, P: +64 (3) 479 5800

**For media assistance, please contact:** Jackie Ellis, P: +64 27 246 2505 E: [jackie@ellisandco.co.nz](mailto:jackie@ellisandco.co.nz)

---

<sup>1</sup> Eligible Shareholders are those persons who were recorded on the Pacific Edge share register at 5.00pm NZST on 22 September 2021 as being a holder of Pacific Edge shares and having an address in New Zealand (Eligible Shareholders).

Note: The information in this email is general information only, does not constitute a securities recommendation or financial product advice, and has been prepared without taking account of the investment objectives, financial situation or needs of any particular investor. As well as publicly available information about Pacific Edge, you should read the Retail Offer Document and consider whether any investment is appropriate having regard to your objectives, financial situation or needs before acting on the information.

**OVERVIEW** [www.pacifedge.co.nz](http://www.pacifedge.co.nz) [www.pacifedgedx.com](http://www.pacifedgedx.com)

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies.

Refer to [www.cxbladder.com](http://www.cxbladder.com) for more information.